TY - JOUR
T1 - Safety and feasibility of radiofrequency ablation using bipolar electrodes for aldosterone-producing adenoma
T2 - a multicentric prospective clinical study
AU - Oguro, Sota
AU - Morimoto, Ryo
AU - Seiji, Kazumasa
AU - Ota, Hideki
AU - Kinoshita, Tomo
AU - Kawabata, Masahiro
AU - Ono, Yoshikiyo
AU - Omata, Kei
AU - Tezuka, Yuta
AU - Satoh, Fumitoshi
AU - Ito, Sadayoshi
AU - Moriya, Nobukazu
AU - Matsui, Seishi
AU - Nishikawa, Tetsuo
AU - Omura, Masao
AU - Nakai, Kazuki
AU - Nakatsuka, Seishi
AU - Kurihara, Isao
AU - Miyashita, Kazutoshi
AU - Koda, Wataru
AU - Minami, Tetsuya
AU - Takeda, Yoshiyu
AU - Kometani, Mitsuhiro
AU - Oki, Yutaka
AU - Oishi, Toshihiro
AU - Ushio, Takasuke
AU - Goshima, Satoshi
AU - Takase, Kei
N1 - Funding Information:
This work was supported by JSPS KAKENHI Grant Number JP20H03613 and 23390296.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Evaluation of feasibility and safety of percutaneous radiofrequency ablation using bipolar radiofrequency devices in a prospective multicenter cohort of patients with benign aldosterone-producing adenoma. A total of five institutions participated. CT-guided percutaneous RFA was performed for patients diagnosed as APA. The safety of the procedure was evaluated using the Common Terminology Criteria for Adverse Events. During the 84-day follow-up period, serial changes in plasma aldosterone concentration and plasma renin activity were measured. The percentage of patients with normalized hormonal activity after the procedure, was calculated with 95% confidence intervals. Forty patients were enrolled, and two patients were excluded for cerebral hemorrhage and no safe puncture root. In another patients, RFA was tried, but an intraprocedural intercostal arterial injury occurred. Consequently, RFA was completed in thirty-seven patients (20 men, 17 women; mean age, 50.4 ± 10.0 year). The tumor size was 14.8 ± 3.8 mm. The treatment success rate of the ablation was 94.6% (35/37), and a 2nd session was performed in 2.7% (1/37) patients. Grade 4 adverse events were observed in 4 out of 38 sessions (10.5%). The normalization of plasma aldosterone concentration or aldosterone-renin ratio was 86.5% (72.0–94.1: 95% confidence interval) on day 84. Percutaneous CT-guided RFA for APA using a bipolar radiofrequency system was safe and feasible with clinical success rate of 86.5% on day 84.
AB - Evaluation of feasibility and safety of percutaneous radiofrequency ablation using bipolar radiofrequency devices in a prospective multicenter cohort of patients with benign aldosterone-producing adenoma. A total of five institutions participated. CT-guided percutaneous RFA was performed for patients diagnosed as APA. The safety of the procedure was evaluated using the Common Terminology Criteria for Adverse Events. During the 84-day follow-up period, serial changes in plasma aldosterone concentration and plasma renin activity were measured. The percentage of patients with normalized hormonal activity after the procedure, was calculated with 95% confidence intervals. Forty patients were enrolled, and two patients were excluded for cerebral hemorrhage and no safe puncture root. In another patients, RFA was tried, but an intraprocedural intercostal arterial injury occurred. Consequently, RFA was completed in thirty-seven patients (20 men, 17 women; mean age, 50.4 ± 10.0 year). The tumor size was 14.8 ± 3.8 mm. The treatment success rate of the ablation was 94.6% (35/37), and a 2nd session was performed in 2.7% (1/37) patients. Grade 4 adverse events were observed in 4 out of 38 sessions (10.5%). The normalization of plasma aldosterone concentration or aldosterone-renin ratio was 86.5% (72.0–94.1: 95% confidence interval) on day 84. Percutaneous CT-guided RFA for APA using a bipolar radiofrequency system was safe and feasible with clinical success rate of 86.5% on day 84.
UR - http://www.scopus.com/inward/record.url?scp=85136148984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136148984&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-18136-5
DO - 10.1038/s41598-022-18136-5
M3 - Article
C2 - 35982148
AN - SCOPUS:85136148984
SN - 2045-2322
VL - 12
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 14090
ER -